Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. More »

Featured News

A profile of Dr. Ted Love, GBT’s CEO, by Haverford College Magazine (pdf)

Recent News

10/11/17Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
10/03/17Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October
09/26/17Global Blood Therapeutics Announces New Employment Inducement Grants
09/06/17Global Blood Therapeutics To Convene Sickle Cell Disease Influencers atĀ Annual Sickle Cell Disease (SCD) Therapeutics Conference

More »

Media Resources

Media Contact

Julie Normart